Product Revenue (Tables)

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Net Product Sales

The following table summarizes total other revenue recognized for the years ended December 31, 2025, 2024 and 2023:

	Year Ended December 31,
	2025	2024	2023
Other Revenue	$	$	$
Amgen royalty revenue	40,733	7,841	—
Novartis broad markets revenue	17,598	18,259	8,859
Research and development service revenue	—	—	79,431
Right to access intellectual property revenue	—	—	104,477
Material rights revenue	—	—	71,980
Other	2,641	4,595	4,180
Total	60,972	30,695	268,927

The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December 31, 2025, 2024 and 2023:

	Year Ended December 31,
	2025	2024	2023
	$	$	$
Research and development service revenue	—	—	72,278
Other 1	—	2,113	5,067
Total	—	2,113	77,345

1 Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.

The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December 31, 2025, 2024 and 2023:

	Year Ended December 31,
	2025	2024	2023
	$	$	$
Research and development service revenue	—	—	7,153
Right to access intellectual property revenue	—	—	104,477
Material rights revenue	—	—	71,980
Novartis broad markets revenue	17,598	18,259	8,859
Total	17,598	18,259	192,469

The table below presents the Company’s net product sales for the years ended December 31, 2025, 2024 and 2023.

	Year Ended December 31,
	2025	2024	2023
	$	$	$
Product revenue - gross	6,730,957	4,786,744	2,718,969
Less: Rebates and sales returns	(1,448,896)	(1,007,198)	(529,117)
Product revenue - net	5,282,061	3,779,546	2,189,852

The following table disaggregates net product revenue by product for the years ended December 31, 2025, 2024 and 2023.

	Year Ended December 31,
	2025	2024	2023
	$	$	$
BRUKINSA®	3,928,489	2,644,226	1,290,396
TEVIMBRA®	737,304	620,836	536,620
XGEVA®	305,979	224,403	92,828
BLINCYTO®	104,224	74,331	54,342
KYPROLIS®	74,974	66,171	39,799
POBEVCY®	47,400	53,509	56,547
Other	83,691	96,070	119,320
Total product revenue - net	5,282,061	3,779,546	2,189,852

Schedule of Accrued Sales Rebates and Returns

The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December 31, 2025 and 2024.

	Rebates, Returns and Other Deductions	Contra AR Accruals	Total
	$	$
Balance at December 31, 2023	139,936	30,435	170,371
Amounts charged against product revenue	491,756	515,442	1,007,198
Payments and credits	(396,092)	(495,178)	(891,270)
Balance at December 31, 2024	235,600	50,699	286,299
Amounts charged against product revenue	657,138	791,758	1,448,896
Payments and credits	(494,205)	(763,331)	(1,257,536)
Balance at December 31, 2025	398,533	79,126	477,659